SSRI risks could limit depression market
‘Leading depression drug makers such as Pfizer, GlaxoSmithKline, and Eli Lilly may face further scrutiny following the release of a new report stating that SSRI treatment increases suicidal tendencies in youths. While the report was keen to stress the positive risk/benefit ratio of the treatment, the suicidality data will no doubt cause alarm, further impacting upon the depression market.
The American College of Neuropsychopharmacology (ACNP) Task Force has concluded that data from clinical trials of selective-5-HT-reuptake-inhibitors (SSRIs) and other new generation antidepressant medications indicate a small increase in the risk of adverse event reports of suicidal thinking or suicide attempts in youths under the age of 18.’
Read more at SSRI risks could limit depression market
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax